Literature DB >> 20665748

The downsides of a major medical advance.

Liana Fraenkel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20665748      PMCID： PMC2990795          DOI： 10.1002/acr.20309

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  11 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 3.  The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.

Authors:  Eric J Boren; Gurtej S Cheema; Stanley M Naguwa; Aftab A Ansari; M Eric Gershwin
Journal:  J Autoimmun       Date:  2008 Feb-Mar       Impact factor: 7.094

Review 4.  A systematic review on communicating with patients about evidence.

Authors:  Lyndal J Trevena; Heather M Davey; Alexandra Barratt; Phyllis Butow; Patrina Caldwell
Journal:  J Eval Clin Pract       Date:  2006-02       Impact factor: 2.431

5.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

Authors:  D T Boumpas; H A Austin; E M Vaughn; J H Klippel; A D Steinberg; C H Yarboro; J E Balow
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

Review 6.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

Authors:  C Mukhtyar; O Flossmann; B Hellmich; P Bacon; M Cid; J W Cohen-Tervaert; W L Gross; L Guillevin; D Jayne; A Mahr; P A Merkel; H Raspe; D Scott; J Witter; H Yazici; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2007-10-02       Impact factor: 19.103

Review 7.  A typology of shared decision making, informed consent, and simple consent.

Authors:  Simon N Whitney; Amy L McGuire; Laurence B McCullough
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

8.  Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.

Authors:  C Talar-Williams; Y M Hijazi; M M Walther; W M Linehan; C W Hallahan; I Lubensky; G S Kerr; G S Hoffman; A S Fauci; M C Sneller
Journal:  Ann Intern Med       Date:  1996-03-01       Impact factor: 25.391

Review 9.  Review article: Progress of treatment in ANCA-associated vasculitis.

Authors:  David Jayne
Journal:  Nephrology (Carlton)       Date:  2009-02       Impact factor: 2.506

10.  Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.

Authors:  C D Radis; L E Kahl; G L Baker; M C Wasko; J M Cash; A Gallatin; B L Stolzer; A K Agarwal; T A Medsger; C K Kwoh
Journal:  Arthritis Rheum       Date:  1995-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.